bêta
IA Trial Radar

Voici les essais cliniques pour Diabète filtrés pour le lieu : Belgique.

Je peux vous aider à comprendre votre état de santé, les traitements ou à trouver des essais cliniques près de chez vous.
Notre outil de recherche ne prend en charge que l'anglais. Pour la recherche et la discussion dans d'autres langues, utilisez l'IA Trial Radar ci-dessus ou sélectionnez les filtres de condition médicale et de lieu ci-dessous.
41 résultats trouvés
 
Pathologie
Diabète
×
 
Mots clés
Surveillance continue du glucose
×
 
Lieux
Belgique
×
 
Sexe
Tous
×
 
Titre de l'étude
Statut
Surveillance continue du glucose chez les femmes atteintes de diabète gestationnel (CORDELIA) NCT06310356
En recrutement
Define Predictors for Posttransplant Diabetes Mellitus Study (DECODE) NCT06440330
En recrutement
Beta Cell Function in (Pre)Type 1 Diabetes NCT01402037
Inconnu
To Evaluate the Change in Glucose Parameters in Adult Patients With Type 1 or Type 2 Diabetes From Europe Using the iCan o3 CGM System for 60 Days Period (DETECT) NCT06904846
Recrutement sur invitation
Comparing Continuous With Flash Glucose Monitoring in Adults With Type 1 Diabetes (ALERTT1) NCT03772600
Terminé
Comparison Between Dexcom G5 Mobile Continuous Glucose Monitoring (CGM) System and the FreeStyle Libre Flash Glucose Monitoring System NCT03602963
Terminé
Prospective Randomized Clinical Trial Assessing the Short Term Clinical Impact of Continuous vs Flash Glucose Monitoring in Children, Adolescents and Young Adults With Type 1 Diabetes (GluMoCAY) NCT04249102
Inconnu
Continuous Monitoring of Glycemic Variability to Predict Dys- and Hyperglycemia in Asymptomatic Type 1 Diabetes NCT05777330
En recrutement
The GLOW Study - The YANG System NCT04782934
Terminé
Are the Continuous Glucose Monitoring Systems Able to Improve Long Term Glycaemic Control in Type 1 Diabetic Patients? NCT00726440
Terminé
Evaluation of Glycemic Control in Adults With Type 1 Diabetes When Switching to Insulin Degludec (GLADE) NCT05434559
Terminé
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL (FUTURE-GLARE) NCT05109520
Terminé
Diabeloop for Kids (DBL4K) NCT03671915
Terminé
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes (DEPICT 1) NCT02268214
TerminéRésultats publiés
Diabeloop for Teens (DBL4T) NCT04725591
Terminé
Proof of Concept - Identification of Patient-specific Parameters for Bolus Calculators for Type 1 Diabetes (POC-IDENTITY-1) NCT03414320
Terminé
A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice (CONNECT 1) NCT05069545
Terminé
Smart MDI Study (CIP343) NCT06645834
Terminé
24 heures de comportements de mouvement chez les adultes atteints de diabète de type 1 (24h-MBs_T1D) NCT06425640
En recrutement
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4) NCT04880850
TerminéRésultats publiés
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec (COMBINE 1) NCT05352815
TerminéRésultats publiés
Hyperglycemia and (Pre)Diabetes in Pediatric Renal and Liver Transplantation. (DIAB-GRAFT) NCT05464043
Terminé
cArdiopulmonary exerCise Test Assessing Multiple bIOmarkers iN Type 1 Diabetes NCT05097339
Terminé
INTERPRET - International Report on Routine Practice of Sensor-enabled Pump Therapy NCT00790088
TerminéRésultats publiés
Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2) NCT02414958
TerminéRésultats publiés
CGM Boosted by Artificial Intelligence for Better Glycaemic Control in T2 Diabetes (MAGIC-T2D) NCT07064499
Actif, ne recrute pas
Cardiac Dysfunction in Adolescents With Type 1 Diabetes: Contribution of Daily-life Glucoregulation and Impact on Cardiorespiratory Exercise Capacity (GIIADMT1) NCT04052919
Terminé
Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes (Onset® 5) NCT02825251
TerminéRésultats publiés
The SHINE Study: Safety of Implant and Preliminary Performance of the SHINE SYSTEM in Diabetic Subjects NCT05597605
Terminé
A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus® NCT00391027
TerminéRésultats publiés
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes (DEPICT 2) NCT02460978
TerminéRésultats publiés
Single Dose Escalation Study of PF-05190457 in Healthy Volunteers NCT01247896
Terminé
MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D) (Meld-ATG) NCT04509791
Terminé
A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function NCT04628481
Interrompu
Une étude pour investiguer l'efficacité du teplizumab comparé au placebo chez les participants âgés de 1 à 25 ans atteints de diabète de type 1 de stade 3 (βETA PRESERVE) NCT07088068
En recrutement
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes (SAFEGUARD) NCT07187531
En recrutement
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes NCT01243424
TerminéRésultats publiés
Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes (DIABIL-2) NCT02411253
Terminé
Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab (PROTECT) NCT03875729
TerminéRésultats publiés
IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study) NCT04524949
Interrompu
Longitudinal Study of the GLUcagon REsponse to Hypoglycemia in Children and Adolescents With New-onset Type 1 DIAbetes (GLUREDIA) NCT06770621
En recrutement